Established 1999
123jump.com - U.S. Financial Information Archive: 90,000 Annual and 10-K reports – 20,000 Global news stories - 3,500 IPO reports - 1,700 - Earnings Calls – 320 Fund Interviews – 10-year Annual earnings on 4,500 stocks – 20 Quarterly earnings on 3,600 stocks – 1,800 IPO prospectuses – 1,200 Economic data releases
     
   
 

Cardionet(BEAT)

 
123Jump Rating: - Avoid   Underwriters: Citigroup
      Lehman Brothers
Status: Priced  
 
Address: 1010 Second Ave.,
FiledDate: 08/17/2007
  San Diego,
   
  CA 92130-1027
Filed Price Range ($): $22.00-24.00
       
Telephone: 619-243-7500 Filed Offer Amount ($ Million): $182.10
       
Fax: Shares Offered (Millions): 6.6
       
Websites: www.cardionet.com Shares Outstanding (Millions): 21.3
       
Management: James Sweeney, Chair./CEO
IPO Date: 03/18/2008
  Gregory Marsh, CFO
   
  Charlie Alvarez, EVP
Final Offer Price ($): $18.00
       
Industry: Healthcare Final Offer Size (Millions of Shares): 4.50
       
Employees: 509 Final Offer Amount ($ Million): $81.00
       
Competitors: CardioNet System
S-1 Forms:
  LifeWatch Corp.
   
   
       
     
     
     
       
 
- Avoid        - Value Gap        - Short-Term Growth        - Long-Term Growth        - Long-Term Value

Company Links
Corporate / History Profile Executives Products Services
Major Stock Holders   (Prior To Offering)

Name

Class A
Fred Middleton 13.60%
H&Q Funds 7.80%
James M. Sweeney 7.10%
Sanderling Ventures and its affiliates 13.50%
Scientific Corporation and its affiliates 12.60%

Major Stock Holders  (After Offering)

Name

Common Stock Class A Class B Class C Class L ADS
Fred Middleton 0% 9.30% 0% 0% 0% 0%
H&Q Funds 0% 5.30% 0% 0% 0% 0%
James M. Sweeney 0% 6.10% 0% 0% 0% 0%
Sanderling Ventures and its affiliates 0% 9.20% 0% 0% 0% 0%

Business Environment

Arrhythmias affect more than four million people in the United States. According to the American Heart Association, arrhythmias result in more than 780,000 hospitalizations and contribute to approximately 480,000 deaths each year. A number of factors can contribute to arrhythmias including cardiovascular disease, high blood pressure, diabetes, smoking, excessive consumption of alcohol or caffeine, illicit drug abuse or stress.

The most prevalent arrhythmia is atrial fibrillation, an arrhythmia that affects approximately 2.2 million Americans and is characterized by a rapid, irregular quivering of the upper chambers of the heart. According to the Framingham Study published in 2004, one in four people over the age of 40 in the United States has a lifetime risk of developing atrial fibrillation, and the incidence of atrial fibrillation increases with age.

According to the American Heart Association, approximately 15% to 20% of the estimated 700,000 strokes that occur annually in the United States are attributable to atrial fibrillation and people with atrial fibrillation are approximately five times more likely to have a stroke.

Ventricular tachycardia is a potentially life-threatening arrhythmia initiated in the lower chambers of the heart. It can interfere with the ability of the heart to pump blood and may degenerate into ventricular fibrillation requiring CPR and defibrillation. It can occur with or without apparent heart disease.

While not an arrhythmia, syncope, or fainting, many times results from an arrhythmia. It is the temporary loss of consciousness because of a sudden decline in blood flow to the brain that may be the result of tachycardia or bradycardia. Syncope accounts for 1% to 3% of emergency department visits and up to 6% of hospital admissions each year in the United States.

Company Strategy
The Company is the leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual\'s health.

Product/Services Portfolio
The Company has developed an ambulatory, continuous and real-time arrhythmia monitoring solution. The CardioNet System incorporates a patient-worn sensor attached to leads that captures ECG data and communicates wirelessly with a compact monitor that analyzes incoming information by applying proprietary algorithms designed to detect arrhythmias and eliminate data noise. The CardioNet System, on average, is worn by the patient for a period of approximately 14 days.

The CardioNet System results in a high diagnostic yield of clinically significant arrhythmias, allowing for real-time detection and analysis as well as timely intervention and treatment.

In a randomized 300-patient clinical study, the CardioNet System detected clinically significant arrhythmias nearly three times as often as traditional loop event monitors in patients who have previously experienced negative or nondiagnostic Holter monitoring.

The lightweight sensor (worn as a pendant or on a belt clip) attached to leads records two channels of ECG. The sensor constantly communicates wirelessly with the monitor, a compact handheld unit which can be tucked into a pocket or purse. The monitor analyzes incoming information from the sensor on a real-time basis by applying proprietary algorithms designed to detect arrhythmias.

The monitor allows two-way wireless communications, enabling the CardioNet Monitoring Center to adjust device parameters, \"check in\" on the patient and pull previous ECG data, over standard telephone lines and through cellular coverage. The monitors allow for text messaging and the Company’s C3 monitor also has voice capabilities. Most other ambulatory devices on the market, such as most event monitors, only support one-way transmissions.

At the CardioNet Monitoring Center, an Independent Diagnostic Testing Facility certified by Medicare, experienced certified cardiac monitoring specialists analyze the sent data, respond to urgent events and report results in the manner prescribed by the physician and monitor patient compliance. The CardioNet Monitoring Center operates 24 hours a day, 7 days per week. The data transmission is accomplished through a wireless cell phone modem in the monitor or through the telephone line modem in the base station.

Investment Analysis
Total revenues for the year ended December 31, 2007 increased to $73.0 million from $33.9 million for the year ended December 31, 2006, an increase of $39.1 million, or 115%.

Cost of revenues for the year ended December 31, 2007 were $25.5 million compared to $12.7 million for the year ended December 31, 2006.

Gross profit increased to $47.5 million for the year ended December 31, 2007, or 65% of revenues, from $21.2 million for the year ended December 31, 2006, or 63% of revenues.

Sales and marketing expenses were $16.0 million for the year ended December 31, 2007 compared to $6.4 million for the year ended December 31, 2006.

Net loss decreased to $0.4 million for the year ended December 31, 2007 from $7.6 million for the year ended December 31, 2006

Income Data 
Year Revenues Costs Oper Income Taxes Net Income EPS
2005 30,937,728 23,669,528 -9,694,907 0.00 -11,463,257 -4.04
2006 33,922,801 25,709,719 -4,487,916 0.00 -7,644,732 -2.63
2007 72,992,186 47,224,157 241,611 0.00 -358,071 -2.89

Balance Sheet Data

Year

Cash Acct Recv. Inventory Total Cur Assets Total Cur Liability PPE Total Assets LT Debt SH Equity
2006 3,909,150 10,496,607 0.00 14,791,298 33,504,696 1,779,043 17,170,069 2,911,115 -19,856,766
2007 18,090,636 22,853,958 0.00 41,374,843 11,999,461 15,094,205 103,039,528 1,655,449 -26,865,079

Cash Flow Summary

Year

Net Cash-Ops Net Cash-Inv Net Cash-Fin Net Change
2005 -5,469,044 -644,550 3,153,621 -2,959,973
2006 -2,912,729 -913,666 4,977,989 1,151,594
2007 -237,639 -58,957,494 73,376,619 14,181,486
 

 

© 1999-2008 123jump.com. All rights reserved